← Back to Search

Cell Therapy

DVX201 for Coronavirus Pneumonia

Phase 1
Waitlist Available
Led By Josh Hill, MD
Research Sponsored by Deverra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to maintain a SpO2 ≥ 93% at rest. Supplemental oxygen to a maximum 4L by low flow O2-delivery is allowed, but not required
i. IL-6 < 150 pg/mL ii. CRP < 100 mg/L (10 mg/dL) iii. Ferritin < 1000 ng/mL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 28 days post infusion
Awards & highlights

Study Summary

This trial is testing an NK cell therapy to see if it can help people with COVID-19. NK cells are a part of the immune system that can kill cells infected by viruses. This study will look at the safety and tolerability of the therapy in patients with COVID-19.

Eligible Conditions
  • Coronavirus Pneumonia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 28 days post infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 28 days post infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of dose limiting toxicities (DLT)
Secondary outcome measures
CRS
Disease progression
Oxygen requirements
+2 more
Other outcome measures
Length of time that DVX201 (NK cells) remain in the blood

Trial Design

1Treatment groups
Experimental Treatment
Group I: DVX201 infusionExperimental Treatment1 Intervention
Subjects will enroll and the MTD and/or the recommended phase 2 dose of DVX201 will be determined utilizing a modified "3+3" enrollment schema. This study will enroll a minimum 3 subjects who each receive a single dose of DVX201 and who are evaluable for toxicities at each dose level. Depending on the occurrence of DLTs and the number of dose levels evaluated, additional subjects may be enrolled (approximately 3-15 additional subjects). All subjects will be followed for 28 days post infusion of DVX201.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DVX201
2021
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Deverra Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Fred Hutchinson Cancer CenterOTHER
555 Previous Clinical Trials
1,334,714 Total Patients Enrolled
Josh Hill, MDPrincipal InvestigatorFred Hutchinson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What degree of risk do participants face while using DVX201?

"The limited information present in the Phase 1 trial of DVX201 earned it a score of 1 for safety."

Answered by AI

Are there current opportunities for patients to participate in this research?

"Affirmative. According to clinicaltrials.gov, this research study is currently in the process of recruiting participants and was initially introduced on August 2nd 2021. The last update to the trial occurred on February 11th 2022; 18 individuals must be enrolled at a single location."

Answered by AI

Are elderly individuals being considered for enrollment into this clinical trial?

"This experiment has an age cutoff of 80 years. All participants must be over 18 to participate."

Answered by AI

How extensive is the pool of participants for this clinical trial?

"Affirmative. The clinicaltrials.gov record states that this trial is seeking additional participants, having first been listed on August 2nd 2021 and most recently updated February 11th 2022. 18 volunteers are needed from a single medical centre."

Answered by AI

Who can participate in this medical research experiment?

"This medical experiment seeks 18 volunteers aged between 18 and 80 who have been infected with covid-19. Essential qualifications include having experienced the onset of symptoms within a week after consenting to participate, exhibiting a SpO2 level above 93% at rest (with supplemental oxygen – up to 4L by low flow O2 delivery - permitted but not essential), and if of reproductive age, agreeing to use an efficient form of contraception for 3 months following treatment."

Answered by AI
~3 spots leftby Mar 2025